Connect to share and comment

Novo Nordisk's IT company to look at independent listing

By Teis Jensen and Shida Chayesteh COPENHAGEN (Reuters) - Danish pharmaceuticals company Novo Nordisk has asked its fully-owned IT subsidiary NNIT to study the possibility of a separate listing on the Copenhagen stock exchange, company officials told Reuters on Wednesday. "We don't think Novo Nordisk are the best owners, and that's why we are looking to see if we can find new co-owners," said Jesper Brandgaard, chief financial officer at Novo Nordisk and chairman of NNIT.

Novo Nordisk mulls listing IT subsidiary

The world's biggest maker of insulin, Novo Nordisk, is mulling a listing of its wholly-owned IT unit, NNIT, on the Copenhagen stock exchange, the subsidiary said on Wednesday. "NNIT informs that the company has been requested by Novo Nordisk to explore the potential for a listing on NASDAQ OMX Copenhagen," the company said in a statement. "The aim is to explore the potential for an IPO (initial public offering) and to evaluate whether a listing of NNIT would support the continued development and value creation of the company," it added.

Denmark's Novo Nordisk sued in U.S. over generic Prandin

COPENHAGEN (Reuters) - Denmark's Novo Nordisk has been sued by a group of healthcare purchasing companies in the United States for allegedly wrongfully keeping generic copies of its Prandin diabetes drug off the market. A spokesman for Novo said on Tuesday the company aimed to get the case dismissed, but had no further comment.

Regulator reports Novo Nordisk to police over statement delay

Denmark's Financial Supervisory Authority said on Tuesday it had reported insulin world leader Novo Nordisk to the police for having hidden crucial information from its shareholders for two days. In February, the Danish pharmaceutical company learnt on a Friday evening that the US Food and Drug Administration had rejected its applications for two new diabetes treatments, but did not share the information until late on Sunday.

Novo to launch mid-stage tests with new diabetes pill

By Ben Hirschler LONDON (Reuters) - Novo Nordisk is about to launch a mid-stage clinical study with a tablet version of a so-called GLP-1 medicine as it steps up the hunt for diabetes pills that can replace injections. The Phase II trial may start as early as next week and will involve approximately 600 patients, Chief Science Officer Mads Krogsgaard Thomsen said on Thursday.

Novo Nordisk recalls batches of diabetes drugs

Batches of Novo Nordisk's diabetes treatments NovoMix 30 FlexPen and Penfill are being recalled, the European Medicines Agency said on Friday. "In the affected cartridges the level of insulin may vary between 50 percent and 150 percent of the labelled insulin units, which could lead to hypoglycaemia or hyperglycaemia," the agency said in a statement. Only a small percentage of cartridges, 0.14 percent, contain the wrong amount, the Danish company said.

Novo Nordisk raises guidance as earnings beat views

Novo Nordisk, the world's biggest producer of insulin for diabetes sufferers, posted on Thursday a rise in quarterly earnings driven by sales of diabetes drug Victoza, and raised its full-year guidance. Net profit in the April to June period rose 26 percent to 6.734 billion kroner (903 million euros, $1.206 billion) from the outcomea year ago, beating a Dow Jones Newswires analyst consensus of 6.5 billion kroner. Revenue grew 10 percent to 17.774 kroner.

Novo Nordisk hit by near $1 billion transfer pricing tax claim: TV

COPENHAGEN (Reuters) - Novo Nordisk <NOVOb.CO>, the world's biggest insulin producer, is facing a tax claim for 5.5 billion Danish crowns ($975 million) from the Danish authorities in a dispute over transfer pricing, local television broadcaster DR said on Monday. According to the report, papers obtained by DR shows that Novo is accused of failing to declare a proper value on two drug patents after they were moved from Denmark to Switzerland, and therefore had paid too little in taxes in Denmark.

Novo Nordisk posts better-than-expected earnings

Danish pharmaceutical group Novo Nordisk, the world's biggest producer of insulin for diabetes sufferers, on Wednesday topped analyst profit expectations for its first quarter of 2013 From January to March, the group posted a net profit of 5.982 billion Danish kroner (802 million euros), as it enjoyed strong sales of its diabetic drug Victoza and "modern insulins." Analysts polled by Dow Jones Newswires predicted 5.85 billion kroner in net profit.

European shares led lower by Novo Nordisk

LONDON, Feb 11 (Reuters) - European equities eased on Monday, continuing the previous week's retreat from multi-month peaks and dragged down by a sharp sell off in Novo Nordisk after its key drug suffered a regulatory approval set-back. The weakness in European equities was fairly broad with all but two sectors in the red. Energy and mining stocks were hit by falling commodity prices while continued political turbulence in Italy and Spain weighed on banks and on their national indexes.
Syndicate content